Homology Medicines Profit Margin

Homology Medicines (FIXX) currently reports a profit margin of Infinity% as of March 2026. That compares with 18.07% in the prior-year period — up Infinity% year over year. That is above the Healthcare sector average of 15.52%. Use the charts on this page to explore Homology Medicines's profit margin history and peer comparisons.

Homology Medicines's profit margin increased from 18.07% to Infinity% — a Infinity% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Homology Medicines's profit margin of Infinity% is higher than the Healthcare sector average of 15.52%. That is roughly Infinity% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Homology Medicines's current Infinity% should be judged against Healthcare norms (sector average: 15.52%) and against FIXX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of Infinity%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.52%. From there, open related valuation or income-statement pages for Homology Medicines, and consider following FIXX for alerts when major investors trade the stock.